ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Ultrasound Therapy for Fibromyalgia and Lyme Disease

Curcumin: The All In One Solution, Part 2

What Are the Benefits of Vitamin K2?

Vitamin D deficiency + high fat diet = metabolic syndrome

Why You Should Take Your Apple Cider Vinegar at Night

Use Burdock Oil to Promote Healthy Hair Growth

Meet Your Weight Loss Goals

People with forms of early-onset Parkinson's disease may benefit from boosting niacin in diet, resea...

AMA journal associates iron deficiency with hearing loss

Why the Mediterranean Diet Is so Successful

 
Print Page
Email Article

Vaccine cuts shingles risk 55%; same for those with & without chronic disease – Kaiser Stats Reported in JAMA

  [ 16 votes ]   [ 1 Comment ]
www.ProHealth.com • January 12, 2011


New data should spur reduction of vaccination “barriers” among clinicians and patients, sparing many the suffering & nerve damage associated with shingles. (Fewer than 7% of seniors get the vaccine now, according to the most recent CDC data.)

Vaccination for herpes zoster, a painful rash commonly known as shingles, among a large group of older adults was associated with a reduced risk (not elimination) of this condition, regardless of age, race or the presence of chronic diseases, according to a study in the January 12 issue of JAMA.(1)

"The pain of herpes zoster is often disabling and can last for months or even years, a complication termed postherpetic neuralgia. Approximately 1 million episodes of herpes zoster occur in the United States annually, but aside from age and immunosuppression, risk factors for this condition are not known," the authors write.

By way of background, though prelicensure data provided evidence that herpes zoster vaccine works in a select study population under idealized circumstances, the vaccine needed to be evaluated in field conditions to show whether benefits of the vaccine can be generalized to conditions of clinical practice.

The researchers note that field testing is particularly important for the herpes zoster vaccine, given the medical and physiological diversity in the elderly population for whom the vaccine is indicated.

Hung Fu Tseng, PhD, MPH, of Southern California Kaiser Permanente, Pasadena, and colleagues evaluated the risk of herpes zoster after receipt of herpes zoster vaccine among individuals in general practice settings.

The study included community-dwelling adults, age 60 years or older, who were members of a managed care organization. There were 75,761 members in the vaccinated cohort, who were age matched (1:3) to 227,283 unvaccinated members.

Compared with the unvaccinated cohort, individuals in the vaccinated cohort were more likely to be white, women, and to have had more outpatient visits, and a lower prevalence of chronic diseases.

There were 5,434 herpes zoster cases identified in the study:

• 6.4 cases per 1,000 persons per year among vaccinated individuals

• And 13.0 cases per 1,000 persons per year among unvaccinated individuals.

In the fully adjusted analysis, vaccination was associated with reduced risk of herpes zoster.

The reduction in risk did not vary by age at vaccination, sex, race, or with presence of chronic diseases.

Herpes zoster vaccine recipients had reduced risks of ophthalmic herpes zoster and hospitalizations coded as herpes zoster.

Overall, the vaccine was associated with a 55% reduction in incidence of herpes zoster.

"Herpes zoster vaccine was licensed recently, which means the durability of its protection needs to be assessed in future studies. Meanwhile, however, this vaccine has the potential to annually prevent tens of thousands of cases of herpes zoster and postherpetic neuralgia nationally,” The authors stated.

“To date,” they add, “herpes zoster vaccine uptake has been poor due to weaknesses in the adult vaccine infrastructure and also due to serious barriers to the vaccine among clinicians and patients.

“Solutions to these challenges need to be found so that individuals seeking to receive herpes zoster vaccine will be able to reduce their risk of experiencing this serious condition."
___

1. “Herpes Zoster Vaccine in Older Adults and the Risk of Subsequent Herpes Zoster Disease [Shingles]” Tseng HF, et al. JAMA, Jan 12, 2011

Source: JAMA news release, Jan 11, 2011




Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Ultra EPA  - Fish Oil Vitamin D3 Extreme™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments Post a Comment

Vaccine cuts shingles risk 55%
Posted by: mspat
Jan 19, 2011
I would be curious to know if this Vaccine would be harmful to Fibromyalgia/CFIDS/ME patients? I have always been told that these patients should not take a live vaccine. Pat Henderson
Reply Reply
 
NAD+ Ignite with Niagen

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Breakthrough Form of Magnesium Enhances Memory and Cognitive Function Breakthrough Form of Magnesium Enhances Memory and Cognitive Function
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH
Complete and Natural Menopause Relief Complete and Natural Menopause Relief
Strengthen Cell Function with Energy-Boosting Niagen Strengthen Cell Function with Energy-Boosting Niagen
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map